Telstran

Telmisartan

Essential HTN. Reduce risk of MI, stroke or death in patients ≥55 yr at high risk of developing major CV events who are unable to take ACE inhibitors. High risk CV events including evidence of CAD, peripheral arterial disease, stroke, transient ischemic attack or diabetes w/ evidence of end-organ damage. Additional treatment to antihypertensive, antiplatelet or lipid-lowering therapy.

Adult Essential HTN 40 mg once daily, may be increased to max: 80 mg once daily. Severe HTN 160 mg alone & in combination w/ hydrochlorothiazide 12.5-25 mg daily. CV risk reduction 80 mg once daily. Mild to moderate hepatic impairment Not to exceed 40 mg once daily.

May be taken with or without food.

Hypersensitivity. Biliary obstructive disorders. Concomitant use w/ aliskiren-containing products in patients w/ DM or renal impairment (GFR <60 mL/min/1.73 m²). Severe hepatic impairment. 2nd & 3rd trimesters of pregnancy. Lactation.

Not recommended in primary aldosteronism & dual blockade of renin-angiotensin-aldosterone system. Not to be used concomitantly w/ ACE inhibitor in patients w/ diabetic nephropathy. Bilateral renal artery stenosis or artery stenosis to single functioning kidney; severe CHF or underlying renal disease including renal artery stenosis; aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy; hyperkalaemia; DM; ischaemic cardiopathy or CV disease; dehydration, acute cardiac decompensation, metabolic acidosis, infectious diseases, cellular lysis. Correct vol &/or Na depletion prior to administration. Concomitant use w/ K-containing salt substitutes, K-sparing diuretics, ACE inhibitors, NSAIDs, selective COX-2 inhibitors, heparin, immunosuppressives, trimethoprim. Black patients. May affect ability to drive & use machines. Not to be given in patients w/ cholestasis, biliary obstructive disorders or severe hepatic impairment. Mild to moderate hepatic impairment. Recent kidney transplantation. Periodic monitoring of serum K & creatinine in patients w/ renal impairment. Not to be initiated during pregnancy. Not recommended during 1st trimester of pregnancy & lactation. Childn & adolescents <18 yr. Elderly >70 yr.

UTI including cystitis, upper resp tract infection; anaemia; hyperkalaemia; insomnia, depression; syncope; vertigo; bradycardia; hypotension, orthostatic hypotension; dyspnoea, cough; abdominal pain, diarrhoea, dyspepsia, flatulence, vomiting; pruritus, hyperhidrosis, rash; back pain, muscle spasms, myalgia; renal impairment; chest pain, asthenia; increased blood creatinine.

Increased digoxin peak plasma & trough conc. Increased risk of hyperkalaemia w/ K-containing salt substitutes, K-sparing diuretics, K supplements, ACE inhibitors, NSAIDs, selective COX-2 inhibitors, heparin, immunosuppressives, trimethoprim. Reversible increased serum lithium conc & toxicity. Reduced antihypertensive effect w/ NSAIDs ie, ASA, COX-2 inhibitors, non-selective NSAIDs. Vol depletion & risk of hypotension w/ high-dose diuretics eg, furosemide or hydrochlorothiazide. Increased BP-lowering effect w/ other antihypertensives. Potentiated hypotensive effects w/ baclofen, amifostine. Aggravated orthostatic hypotension w/ alcohol, barbiturates, narcotics or antidepressants. Reduced antihypertensive effect w/ systemic corticosteroids.

Angiotensin II Antagonists

C09CA07 - telmisartan ; Belongs to the class of angiotensin II receptor blockers (ARBs). Used in the treatment of cardiovascular disease.

B